RxDoctor Payments Data

P.p Echegaray Mendez, MD

Internal Medicine · Guaynabo, PRNPI 1639124977

Payments from drug & device makers

$3,641in general payments, 2019–2025

Across 102 payments — averaging $35.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$497
  • Boehringer Ingelheim$374
  • Sanofi$251
  • Amgen$120
  • Mallinckrodt Hospital Products Inc.$100
  • plus $241 from 7 others

What the payments were for

  • Speaking & faculty fees$1,45040%
  • Food & beverage$2,08257%
  • Education$1093%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,641 in reported general payments places this provider in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$115,145
Medicare patients
237
Services billed
2,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat42$576,179
Spiriva RespimatTiotropium Bromide604$326,861
Breo ElliptaFluticasone/Vilanterol727$303,397
OfevNintedanib Esylate21$274,147
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate921$224,357
SymbicortBudesonide/Formoterol Fumarate732$176,285
Trelegy ElliptaFluticasone/Umeclidin/Vilanter236$156,870
Stiolto RespimatTiotropium Br/Olodaterol Hcl231$112,806
FasenraBenralizumab13$74,724
Montelukast Sodium4,558$48,393
Pirfenidone25$46,675
Wixela InhubFluticasone Propion/Salmeterol302$45,567
Albuterol Sulfate HfaAlbuterol Sulfate999$38,986
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$38,373
Atrovent HfaIpratropium Bromide58$27,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Ofev, Stiolto Respimat$374$713,814856 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$497$479,4401,031 claims
AstraZenecaSymbicort, Fasenra, Breztri Aerosphere, Pulmicort Flexhaler$2,059$293,853821 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$81$4,91917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Guaynabo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →